Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A-CHOP-14 (elderly)
2007-000821-23Phase 3Completed
- Sponsor
- Universitätsmedizin Göttingen
- Start
- Mar 2007
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of alemtuzumab in T-cell lymphoma and lymphosarcoma (2 arms), sponsored by Universitätsmedizin Göttingen. Primary endpoint: Event-free survival at 3 years. Started Mar 2007; status: completed.
02
Drugs
alemtuzumab
03
Conditions
T-cell lymphomalymphosarcoma
Beyond the preview
Go deeper on 2007-000821-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000821-23.